O avanço da técnica crispr-cas9 ante à perspectiva bioética do direito internacional

Abstract

The Set of Regularly Spaced Palindromic Repeats in association with the Cas9 nuclease, or CRISPR-Cas9, was developed by scientists Emmanuelle Charpentier, the director of the Max Planck Institute for Infection Biology, and Jennifer A. Doudna, a biochemist at the University of California Berkeley. This genetic engineering technique is a way of editing the human genome, enabling countless advantageous possibilities in terms of treating pathologies and prolonging life expectancy. However, the technique also catalyzes fears regarding the normative and bioethical aspects of the procedure. Thus, throughout this article, the complexities inherent in the lack of precise regulation regarding the use of this technology are addressed, thereby promoting an analysis of the need to establish discernible boundaries between the legitimate search for genetic improvements and the imminent risk of unbridled eugenics. Furthermore, it is imperative to examine the implications of CRISPR-Cas9 on the fundamental principles that permeate society, considering not only the benefits but also the intrinsic ethical challenges. With the aim of achieving the outlined purposes, this research employs a methodological approach anchored in applied bibliographical research, enabling a careful analysis of the impact of this technique. Through a critical investigation into the contingencies resulting from genetic engineering and its confluence with bioethical postulates, this study aims to contribute to a more in-depth understanding of the ethical and legal implications of the CRISPR-Cas9 technique.